AREDS2 STUDY PDF
Welcome to The Age-Related Eye Disease Study 2 (AREDS2) was a multi-center, randomized trial designed to assess the effects of oral. The Age-Related Eye Disease Study 2 (AREDS2) Research Group* . AREDS2 was designed to test whether adding lutein + zeaxanthin, DHA. Lutein + Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration: The Age-Related Eye Disease Study 2 (AREDS2).
|Published (Last):||9 October 2004|
|PDF File Size:||10.55 Mb|
|ePub File Size:||20.53 Mb|
|Price:||Free* [*Free Regsitration Required]|
Follow-up study visits were scheduled annually; follow-up also included telephone contact 3 months after arrds2 and subsequent telephone contacts at 6 months between study visits.
As a service to our customers we are providing this early version of the manuscript. The components and the manufacturing details of the study medications including the placebos for both randomization schemes are described in Appendix 2 available at http: The results from analyses without the stratification by secondary interventions were very similar to these results.
Likelihood of adherence to the study regimen was evaluated during a run-in phase using study placebo and the AREDS formulation. The details of the study design have been reported previously.
Participants were able to select more than 1 racial category. Funds were generously contributed to these contracts by the following NIH institutes: Eye Diseases Prevalence Research Group.
AREDS2 Results Released
It is also important to talk to your ophthalmologist regarding taking appropriate supplements. Participants with less than large drusen in both eyes or in study eye. Analyses of each secondary outcomes listed below arefs2 be adjusted for baseline levels of covariates. Other factors to consider include inadequate dose, inadequate duration of treatment, or both.
Large drusen in one eye, less than large drusen fellow eye c. J Am Stat Assoc.
AREDS2 Results Released | Macular Disease Foundation Australia
Because of the potential for increased risk of mortality with beta carotene, analyses for competing risk were performed. J Am Stat Assoc. However, these results will be clinically important for most persons who are at risk for developing AMD. The primary stury outcome, time to progression to advanced AMD, will be assessed using a Cox proportional hazards model without adjustment for covariates.
The contributing institutes from ared2 NIH were consulted for various aspects of the study, including its design and conduct. There was no apparent effect of beta carotene elimination or lower-dose zinc on progression to advanced AMD. Get free access to newly published articles. Study Flow and Randomization. The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina.
AREDS2 is powered to assess a similar further reduction in the treatment arms compared with the control arm, which would be considered clinically important.
Table 2 reports the distribution of randomization of the variations of the AREDS formulation as well as participants who chose to take the AREDS formulation within each of the treatment groups in the primary randomization. Persons who did not consent to this secondary randomization but who agreed to take the original AREDS supplements, provided they were not current or former smokers within the past year, were allowed to participate in the study. Lutein stuxy age-related ocular disorders in the older adult: Oral docosahexaenoic acid in the prevention of exudative age-related macular degeneration: It is not known whether a single specific ingredient is important or if the combination is essential for its therapeutic effect.
Effects of alpha-tocopherol and beta-carotene supplements on sutdy incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study. Institutional review boards approved the AREDS2 research protocol, and all participants provided written informed consent.
Design Multicenter phase 3 randomized controlled clinical trial.
The following material should appear online only: Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: